US Patent Issued to Tolremo Therapeutics on Nov. 18 for "Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer" (Swiss, Polish Inventors)

ALEXANDRIA, Va., Nov. 18 -- United States Patent no. 12,472,179, issued on Nov. 18, was assigned to Tolremo Therapeutics AG (Muttenz, Switzerland).

"Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer" was invented by Stefanie Fluckiger-Mangual (Muttenz, Switzerland), Dorothea Gruber (Muttenz, Switzerland), Thomas Bohnacker (Muttenz, Switzerland), Martin Schwill (Muttenz, Switzerland), Debora Schmitz-Rohmer (Muttenz, Switzerland), Charles-Henry Fabritius (Muttenz, Poland) and Sara Laudato (Muttenz, Switzerland).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention is inter alia concerned with (i) a combination of a CBP/p300 bromodomain inhibitor and ...